Clinical Trials Browser

INDUSTRY × Breast Neoplasms × margetuximab × Clear all

NCT01828021 2025-03-13

Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer

Phase 2 Completed

25 enrolled 8 charts

Breast Neoplasms, Recurrence

NCT01148849 2025-02-26

Safety Study of MGAH22 in HER2-positive Carcinomas

Phase 1 Completed

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms